Equity
€98,180 from €415,121 in 2023
Equity fell by 76% in 2 years.
Pharmadons
Lifetime
19 annual accounts with figures on one time axispeak €224,906 (2020)
€110,101▼ 26.4%
lowest -€56,077 (2008)
-€9,746▼ €2,551
peak €415,121 (2023)
€98,180▼ 75.9%
€510,695▲ 305%
peak 3.4 FTE (2017)
1.3 FTE▼ 35.0%
Board2 names since 2021
1 directorBDM PHARMA
Documentsfilings and deeds
14-08-202614 days late
2025abbreviated format
Gross margin from €149,579 to €110,101Loss of €9,746Staff from 2 FTE to 1.3 FTEDividend €300,000Equity from €407,926 to €98,180Debts from €126,234 to €510,695
Key points
from the 2025 annual accountsLosses
-€16,941 in two years
The 2024 and 2025 financial years closed with a loss. 2025 was the heaviest.
Debts
€510,695 84% of the balance sheet
Financial debts 6%Suppliers 27%Taxes and wages 3%Other 65%
Of this, €497,590 falls due within a year.
Investments
€7,235 3.5 × depreciation
Green is investment, beige is depreciation.
Liquidity
1.19 was 4.39 in 2024
Short-term debts rose from €120,412 to €497,590.
Filings
19 annual accounts since 2007
Three of the last ten came late. The 2022 accounts came latest: 28 days after the end of the period.
Checked score
78
Excellent
Financially stronger than 19% of micro companies in retail trade (NACE 47)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.5% Low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.6% across 40,277 companies (NACE 47, micro).
About 5 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024lowest value
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025
08-2025: < 0.1%● unchanged vs 07-2025
09-2025: 0.2%▲ +0.2 percentage points vs 08-2025
10-2025: 0.2%● unchanged vs 09-2025
11-2025: 0.2%● unchanged vs 10-2025
12-2025: 0.2%● unchanged vs 11-2025
01-2026: 0.2%● unchanged vs 12-2025
02-2026: 0.2%● unchanged vs 01-2026
03-2026: 0.2%● unchanged vs 02-2026
04-2026: 0.2%● unchanged vs 03-2026
05-2026: 0.2%● unchanged vs 04-2026
06-2026: 0.2%● unchanged vs 05-2026
07-2026: 0.2%● unchanged vs 06-2026
08-2026: 0.4%▲ +0.2 percentage points vs 07-2026
09-2026: 0.5%▲ +0.1 percentage points vs 08-2026highest value
10-2026: 0.5%● unchanged vs 09-2026highest value
11-2026: 0.5%● unchanged vs 10-2026highest value
Financial strengthWeak
Score breakdown
raises risk
Equity €98,180 (16.1% of total assets)
Sector: Retail trade (NACE 47)
lowers risk
Size: 1.3 FTE, total assets €608,875
Figures for financial year 2025 (filed on 21-08-2026)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 32% of them on solvency, 15% on liquidity, 21% on profitability and 8% on growth.
The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the low class on 30-06-2025, 0.8% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 2,166 companies had the same profile as Pharmadons has now. Each dot stands for 6 companies, two years later.
94.2%
were still trading
3.0%
stopped another way
2.5%
went bankrupt
Another 0.3% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of Pharmadons itself is lower: 0.5% within 12 months. It rests on far more data about Pharmadons than the profile alone.
Test of the method
The method was tested on the 497,448 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 2,166 companies, not a prediction for Pharmadons. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €7,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.19 (4.39 in 2024), below the usual 1.5. Short-term debt is 81.7% and cash 8.2% of total assets. 83.9% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises risk
raises risk · 2025 accounts filed 14 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 14-08-2026, 14 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
14 days late
2024
11 days late
2023
36 days early
2022
28 days late
2021
38 days early
2020
26 days early
2019
25 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 10 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 11 August (4 of the last 5 accounts filed within 46 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
11-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0885520423
1 director appointed, 1 resignation
Appointment: BDM PHARMA SRL · Permanent representative: Mélissa DAMTCHOU MBITOM · Resignation: Stéphane LAMBERT · General meeting of 01-07-2024 · Gazette deed
Resignation: LAMBERT Stéphane Urbain Henri (manager)
Reappointment: LAMBERT Stéphane Urbain Henri (director) · General meeting of 09-01-2024 · Gazette deed
First establishment
François Donsstraat 32, Ixelles
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Pharmadons Ixelles | €608,875 | €110,101 | 16.1% | 1.3 |
| PHARMACIE DES FLEURISTES Brussels | €503,835 | €116,877 | 36.2% | 1 |
| SENNE PHARMA Soignies | €617,578 | €126,239 | 32.0% | 1.5 |
| DEMAPHARMA Ottignies-Louvain-la-Neuve | €659,253 | €122,780 | 58.5% | 1 |
| APOTHEEK MEES TILDONK Haacht | €491,660 | €103,198 | 32.5% | 1.3 |
| PHARMAGILLY Charleroi | €717,024 | €120,224 | 26.3% | 1.3 |
| UNIPHARM Veurne | €716,027 | €128,221 | 51.6% | 1.5 |
These companies have the same main activity as Pharmadons: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €492,000 and €717,000, founded between 2003 and 2007.
Official details
Source: KBO- Status
- Active since 08-12-2006Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2023
- Establishment unit
- 2.158.251.5821050 Ixelles, since 28-12-2006
- Financial year end
- 31 December
- Peppol
- Reachable since 04-12-2025
Annual accounts 2025
- ≈ €510,000estimated
- €608,875▲ 14.0%
- Employeeson 31-12-2025
- 2=
- Filing
- Filed on 14-08-2026
Insights on Pharmadons
Pharmadons files the abbreviated format. That format states no turnover. The gross margin fell from €183,679 in 2007 to €110,101 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Pharmadons
- What is the company number of Pharmadons?
- The company number of Pharmadons is 0885.520.423. The VAT number is the same number with BE in front: BE 0885.520.423.
- Where is Pharmadons based?
- The registered office is at François Donsstraat 32, 1050 Ixelles.Company details
- What does Pharmadons do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of Pharmadons?
- Pharmadons is a private limited company (BV).
- When was Pharmadons founded?
- Pharmadons was founded on 08-12-2006.
- Is Pharmadons still active?
- Yes, Pharmadons is an active enterprise in the KBO register.
- How many employees does Pharmadons have?
- Pharmadons had an average of 1.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does Pharmadons fall under?
- In its 2023 annual accounts, Pharmadons states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of Pharmadons?
- The turnover in financial year 2025 is ≈ €510,000. This figure is estimated from the gross margin of €110,101 and 51 comparable companies (NACE 477). It probably lies between €340,000 and €1.0m.
- Is Pharmadons profitable?
- In financial year 2025, Pharmadons made a loss of €9,746.
- Where can I find the annual accounts of Pharmadons?
- Pharmadons filed 19 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Pharmadons due?
- Pharmadons must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.